Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa, Alessandro M. Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Janos Jakucs, Andrew Perkins, Ritam Prasad, Jiri Mayer, Judit Demeter, Peter Ganly, Jack W. Singer, Huafeng Zhou, James P. Dean, Peter A. te Boekhorst, Jyoti Nangalia, Jean Jacques Kiladjian, Claire N. Harrison
Dive into the research topics of 'Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial'. Together they form a unique fingerprint.